| abstract |
Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially long er half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis. |